# PRAF2

## Overview
PRAF2, or PRA1 domain family member 2, is a gene located on the X chromosome that encodes a transmembrane protein involved in intracellular protein transport and membrane trafficking. The PRAF2 protein is characterized by its four transmembrane domains and a prominent PRA1 domain, which facilitates protein-protein interactions, particularly within the endoplasmic reticulum and Golgi apparatus (Fo2006Genomic). Functionally, PRAF2 acts as a gatekeeper, regulating the export of certain G protein-coupled receptors, such as CCR5, to the cell surface, thereby influencing processes like chemotaxis and HIV-1 entry (Da2023Control). Additionally, PRAF2 interacts with apoptosis-regulating proteins, such as Bcl-xL, and is implicated in various cancers, where its overexpression is associated with poor prognosis and aggressive tumor behavior (Vento2010Praf2; Wang2018PRAF2). The protein's involvement in vesicular trafficking and cellular signaling underscores its significance in both normal cellular function and disease states.

## Structure
The PRAF2 protein is encoded by the PRAF2 gene located on human chromosome Xp11.23. It is composed of 178 amino acids, with a predicted molecular mass of approximately 19.3 kDa (Fo2006Genomic). The protein features a large PRA1 domain, which is characteristic of the PRAF protein family and is involved in protein-protein interactions (Fo2006Genomic). PRAF2 contains four transmembrane domains, suggesting it is an integral or membrane-associated protein, predominantly associated with the endoplasmic reticulum (ER) (Fo2006Genomic). 

The protein's structure includes two highly conserved domains and two putative phosphorylation sites at tyrosine 43 (Y43) and serine 97 (S97), with Y43 being highly conserved. These sites suggest potential post-translational modifications by protein kinase A (PKA) and protein kinase C (PKC) (Fo2006Genomic). PRAF2 may exist in different structural conformations, allowing it to integrate with membranes or exist in a soluble form in the cytoplasm (Fo2006Genomic). The protein's topography model predicts that both termini are directed towards the cytoplasm, connected through an intracellular loop (Fo2006Genomic).

## Function
PRAF2 (PRA1 domain family member 2) is a protein involved in the regulation of intracellular protein transport and membrane trafficking processes. It is primarily associated with the endoplasmic reticulum (ER) and Golgi apparatus, playing a crucial role in vesicle-mediated transport. PRAF2 acts as a gatekeeper protein, retaining certain G protein-coupled receptors (GPCRs) within the ER, thereby regulating their export to the cell surface. This function is particularly significant for the chemokine receptor CCR5, where PRAF2 interacts through transmembrane domains to inhibit its plasma membrane export, influencing processes like chemotaxis and HIV-1 cell entry (Da2023Control).

PRAF2 is also involved in the regulation of other proteins, such as the GABA B receptor subunit GB1, by controlling its retention in the ER and affecting receptor density on the cell surface (CifuentesDiaz2015Anatomical). The protein is expressed in various human tissues, including the brain, where it is implicated in neuronal development and function, influencing synaptic transmission and plasticity (Fo2006Genomic). PRAF2's role in vesicular trafficking and protein transport suggests it has broader implications in cellular signaling and function in healthy human cells (Da2023Control).

## Clinical Significance
PRAF2 (PRA1 domain family member 2) is implicated in several cancers, where its overexpression is associated with poor prognosis and aggressive tumor behavior. In hepatocellular carcinoma (HCC), PRAF2 overexpression enhances cell proliferation and migration, leading to faster tumor growth and increased metastasis, particularly in the lungs. High PRAF2 expression in HCC tissues correlates with shorter overall survival, making it an independent prognostic factor (Wang2018PRAF2).

In esophageal squamous cell carcinoma (ESCC), PRAF2 is overexpressed in tumor tissues compared to normal tissues. This overexpression is linked to lower differentiation grades and higher TNM stages, indicating more aggressive cancer. Silencing PRAF2 in ESCC cells reduces proliferation and invasion, while inducing apoptosis, suggesting its role in tumorigenesis and metastasis (Qian2019PRAF2).

PRAF2 also plays a significant role in neuroblastoma, where its high expression is associated with poor clinical outcomes, including advanced disease stages and MYCN amplification. Knockdown of PRAF2 in neuroblastoma cells results in reduced proliferation and migration, indicating its involvement in tumor progression (YCO2013PRAF2).

In breast cancer, PRAF2 is upregulated and associated with advanced clinical stages and lymph node metastasis. Its downregulation affects cell migration and proliferation, implicating it in cancer progression through pathways like Wnt/β-catenin signaling (Wang2022PRAF2).

## Interactions
PRAF2 interacts with several proteins, playing a significant role in cellular processes such as apoptosis and vesicular trafficking. It has been identified as a novel interacting partner of Bcl-xL and Bcl-2, both members of the Bcl-2 family involved in regulating apoptosis. The interaction between PRAF2 and Bcl-xL is dependent on the transmembrane domain of Bcl-xL, and this interaction is crucial for modulating apoptosis. Overexpression of PRAF2 can induce apoptotic cell death, which is inhibited by full-length Bcl-xL but not by a mutant lacking the transmembrane domain (Vento2010Praf2).

PRAF2 also interacts with the chemokine receptor CCR5, a G protein-coupled receptor. This interaction occurs through the transmembrane domains of CCR5, rather than the carboxyterminal tail, and acts as a gatekeeper by inhibiting the plasma membrane export of CCR5. This interaction is significant for the regulation of CCR5's cell-surface expression, which is crucial for its role as a co-receptor for HIV-1 entry (Da2023Controla).

Additionally, PRAF2 is suggested to interact with Reticulon family proteins, such as RTN4, which modulate cell death by influencing the subcellular localization of Bcl-xL/Bcl-2 (Vento2010Praf2).


## References


[1. (CifuentesDiaz2015Anatomical) Carmen Cifuentes-Diaz, Stefano Marullo, and Stéphane Doly. Anatomical and ultrastructural study of praf2 expression in the mouse central nervous system. Brain Structure and Function, 221(8):4169–4185, December 2015. URL: http://dx.doi.org/10.1007/s00429-015-1159-8, doi:10.1007/s00429-015-1159-8. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00429-015-1159-8)

[2. (Wang2018PRAF2) Chun-Hua Wang, Li-Li Liu, Ding-Zhun Liao, Mei-Fang Zhang, Jia Fu, Shi-Xun Lu, Shi-Lu Chen, Hong Wang, Shao-Hang Cai, Chris Zhiyi Zhang, Hui-Zhong Zhang, and Jing-Ping Yun. Praf2 expression indicates unfavorable clinical outcome in hepatocellular carcinoma. Cancer Management and Research, Volume 10:2241–2248, July 2018. URL: http://dx.doi.org/10.2147/CMAR.S166789, doi:10.2147/cmar.s166789. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.2147/CMAR.S166789)

[3. (Vento2010Praf2) Maria Teresa Vento, Valeria Zazzu, Alessia Loffreda, Justin R. Cross, Julian Downward, Maria Patrizia Stoppelli, and Ingram Iaccarino. Praf2 is a novel bcl-xl/bcl-2 interacting protein with the ability to modulate survival of cancer cells. PLoS ONE, 5(12):e15636, December 2010. URL: http://dx.doi.org/10.1371/journal.pone.0015636, doi:10.1371/journal.pone.0015636. This article has 34 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0015636)

[4. (Fo2006Genomic) Crystal S. Fo, Craig S. Coleman, Christopher J. Wallick, Alex L. Vine, and André S. Bachmann. Genomic organization, expression profile, and characterization of the new protein pra1 domain family, member 2 (praf2). Gene, 371(1):154–165, April 2006. URL: http://dx.doi.org/10.1016/j.gene.2005.12.009, doi:10.1016/j.gene.2005.12.009. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.gene.2005.12.009)

5. (Da2023Control) Control of CCR5 Cell Surface Targeting by the PRAF2 Gatekeeper. This article has 0 citations.

[6. (Qian2019PRAF2) Zhaoye Qian, Bin Wei, Yu Zhou, Qiuzi Wang, Jiru Wang, Yuan Sun, Yong Gao, and Xiaofei Chen. Praf2 overexpression predicts poor prognosis and promotes tumorigenesis in esophageal squamous cell carcinoma. BMC Cancer, June 2019. URL: http://dx.doi.org/10.1186/s12885-019-5818-7, doi:10.1186/s12885-019-5818-7. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12885-019-5818-7)

[7. (YCO2013PRAF2) LISETTE P. YCO, DIRK GEERTS, JAN KOSTER, and ANDRÉ S. BACHMANN. Praf2 stimulates cell proliferation and migration and predicts poor prognosis in neuroblastoma. International Journal of Oncology, 42(4):1408–1416, February 2013. URL: http://dx.doi.org/10.3892/ijo.2013.1836, doi:10.3892/ijo.2013.1836. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ijo.2013.1836)

[8. (Wang2022PRAF2) Yabing Wang, Zhiyong Zhao, Wei Jiao, Zhaocai Yin, Wanjun Zhao, Hongguang Bo, Zilin Bi, Bingbin Dong, Bin Chen, and Zheng Wang. Praf2 is an oncogene acting to promote the proliferation and invasion of breast cancer cells. Experimental and Therapeutic Medicine, November 2022. URL: http://dx.doi.org/10.3892/etm.2022.11674, doi:10.3892/etm.2022.11674. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/etm.2022.11674)

[9. (Da2023Controla) Elisa Da Silva, Mark G. H. Scott, Hervé Enslen, and Stefano Marullo. Control of ccr5 cell-surface targeting by the praf2 gatekeeper. International Journal of Molecular Sciences, 24(24):17438, December 2023. URL: http://dx.doi.org/10.3390/ijms242417438, doi:10.3390/ijms242417438. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms242417438)